Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tagraxofusp for Post-Transplant Maintenance in CD123+ AML, MDS, MF, and CMML
NCT05233618Phase 1Active, not recruiting
- Start
- Jul 2022
- Primary completion
- Oct 2026
- Modality
- Immunotoxins, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tagraxofusp in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), myelofibrosis (MF) and 1 more. Primary endpoints: Incidence and severity of grade >= 3 adverse events, Dose limiting toxicities at 8 weeks and 1 more. Started Jul 2022; status: active, not recruiting.
02
Drugs
tagraxofusp
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)myelofibrosis (MF)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT05233618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05233618.